Identifying the right drug for the right patient is a universal challenge in cancer drug development. Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, commonly described by cell-of-origin (COO) molecular subtypes. Focusing on well-defined patient subgroups is a...
Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent
